April 10, 2020
Add to Twitter   English | عربي  
 
Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance
• Net sales and EBITDA exceeded raised full-year guidance as a result of continued execution of the three strategic growth drivers

• Etienne Jornod to step down as Executive Chairman. Jacques Theurillat proposed to be elected as new Chairman

• Stefan Schulze appointed CEO Vifor Pharma Group

• Ferinject® / Injectafer®: Blockbuster status achieved one year earlier than anticipated

• Nephrology portfolio driven by strong US performance of Velphoro® and Mircera®

• Veltassa® delivered significant growth in the US by expanding the hyperkalaemia market